Alkermes, Takeda show encouraging data on narcolepsy drugs

Taking stock of the drug industry, from the lab to the medicine chest

September 8, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Ruby Wallau for STAT STAT+ | Alkermes, Takeda show encouraging data on narcolepsy drugs The companies are hopeful that a new class of medicines can eventually treat sleepiness tied to a wide range of conditions. By Elaine Chen STAT+ | Biotech veteran Harvey Berger takes over as CEO of billionaire-backed Arena Bioworks The research institute, which has said it has taken inspiration from the storied Bell Labs, has been experiencing a period of transition. By Allison DeAngelis STAT+ | Rapport shares soar after successful mid-stage seizure trial The company said it planned to launch Phase 3 trials of the drug, called RAP-219, in focal onset seizures next year. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser